Sign in
CompletedNo phase

Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX

Key facts

Who runs it
Institute of Tropical Medicine, Belgium
Where
Belgium, Burkina Faso, and Mozambique3 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
458 people enrolled
Started
13 Dec 2023
Ended
9 Dec 2025
Type of study
Observational, 7 groups
Record updated
11 March 2026

Who can take part

Age
1 year and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age: ≥ 1 year
  • Willing and able to provide written informed consent (or assent for minors with written informed consent by parent(s) and/or guardian(s); Pilot:; -symptomatic for P. falciparum; -/Travel to P. falciparum endemic area within the last month; WP1:
  • Resident in Nanoro district
  • non-symptomatic individuals; WP2:
  • Positive for P. falciparum infection via Rapid Diagnostic Tests (RDT)
  • Age: ≥ 1 and ≤ 12 years
  • Patients are included when suspected of the following conditions:
  • Severe malaria by infection with P. falciparum is defined in the presence of P. falciparum asexual parasitemia, and as one or more of the following:
  • Impaired consciousness: A Blantyre coma score < 3 (when patients are ≤ 6 years) or Glasgow coma score < 10 (when patients are ≥ 6 years)
  • Prostration: Generalized weakness so that the person is unable to sit, stand or walk without assistance
  • Multiple convulsions: More than two episodes within 24 hours
  • Clinical manifestation of respiratory distress (e.g., rapid, deep and labored breathing)
  • Diagnosis through exclusion: absence of an identified alternative cause
  • Uncomplicated malaria by infection with P. falciparum is defined as a patient who presents with lethargic profile (e.g. fever) and a positive parasitological test for P. falciparum, but with no features of severe malaria

Who cannot take part

  • Previous malaria treatment or prophylaxis in the last week
  • Delayed developmental status or history of chronic illness
  • Symptoms of malaria, as defined by presence of fever (body temperature >37.5 °C or history of fever during the past 48 hours) with a positive RDT (RDT are performed always when there is presence of fever)
  • A questionnaire will be used during the clinical assessment that addresses following exclusion criteria:; x Antimalarial drug treatment or other medication during the past week x If the patient had a meal within 4 hours before admission x Patients with acute meningitis (as clinically evaluated according to the local guidelines) x Patients with developmental delay or history of chronic illness x Vaccination during the past week
  • Participation in another study
  • Inability or unwillingness of the parents or guardians to provide informed consent; WP1:
  • Any plans to leave the study are in the coming 10 days; WP2:
  • Severe anemia (will be determined via clinical examination), since blood samples can hardly be withdrawn, co-morbidities

Where is this trial?

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. A new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion rates in natural infections.

The 7 groups in the trial

  • Pilot study Belgium Patients

    Patients (P. falciparum-infected) No intervention 6 ml of venous blood sampled at one time point

  • Pilot study Belgium Controls

    Control non-infected individuals No intervention 6 ml of venous blood sampled at one time point

  • Work package 1 Burkina Faso Asymptomatic

    Asymptomatic (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point. 300µl of finger prick blood at four follow-up visits 24, and 48 and 72h and day 10 after the enrollment.

  • Work package 1 Burkina Faso uncomplicated patients

    uncomplicated patients (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point.

  • Work package 1 Burkina Faso Uncomplicated Malaria Patients

    Control non-infected individuals No intervention Venous blood sample (maximum of 6 ml) at 1 time point.

  • Work package 2 Mozambique Uncomplicated malaria patients

    Uncomplicated malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.

  • Work package 2 Burkina Faso Severe malaria patients

    Severe malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
11 March 2026